Data is being collected. The dashboard will appear when it is available.
SYMBOL
Data is being collected. The dashboard will appear when it is available.
HELP

Close price

$4.85

Latest price

$5.17

Change vs close

+6.60%

Current price: $5.17

Market cap

254.68M

Pre-market and after-hours data may be partial or delayed depending on the source and licensing.

Cybin Inc.

HELP

NASDAQ-GM · Health Care · Biotechnology: Pharmaceutical Preparations

Company Profile

Helus Pharma, the commercial operating name of Cybin Inc. (the 'Company' or 'Helus Pharma') is a clinical stage pharmaceutical company committed to helping minds heal by developing proprietary NSAs - novel serotonergic agonists: synthetic molecules designed to activate serotonin pathways that are believed to promote neuroplasticity. The Company's proprietary NSAs are intended to address the large unmet need for people who suffer from depression, anxiety, and other mental health conditions. With class leading data, Helus Pharma aims to improve the treatment landscape through the introduction of NSAs that provide durable improvements in mental health. Helus Pharma is currently developing HLP003, a proprietary NSA, in Phase 3 clinical development for the adjunctive treatment of major depressive disorder that has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration and HLP004, also a proprietary NSA in Phase 2 for generalized anxiety disorder.

Website

https://www.helus.com/

Country

Ontario, Canada

Sector

Health Care

Industry

Biotechnology: Pharmaceutical Preparations

CIK

0001833141

Candlestick Chart

1D · Data source: loading

Loading candle data

Quarterly Performance Snapshot

Actual revenue and net income based on quarterly filings

Q4 Jul 2026

Quarterly Snapshot

Q4 Jul 2026

Not enough market cap, revenue, or net income data for the selected quarter.

Revenue

Forecast

0

Previous quarter

No data

Net income

Forecast

-47.37M

Previous quarter

-11.02%

Revenue and Net Income Trend

RevenueNet income

Quarterly Performance

13 quarters

Financial Statements

SEC Filings

12 filings shown

Open the original SEC filings to view the full document.

FormFiling DateReport DateAccessionLink
FWPJun 24, 2026No data0001062993-26-003321Document
6-KJun 11, 2026Jun 11, 20260001833141-26-000039Document
6-KJun 1, 2026Jun 1, 20260001833141-26-000036Document
SCHEDULE 13G/AMay 15, 2026No data0000919574-26-003491Document
SCHEDULE 13GMay 15, 2026No data0000919574-26-003218Document
6-KMay 4, 2026Apr 30, 20260001833141-26-000034Document
6-KApr 30, 2026Apr 30, 20260001833141-26-000032Document
6-KApr 28, 2026Apr 28, 20260001833141-26-000030Document
6-KApr 23, 2026Apr 23, 20260001833141-26-000028Document
SCHEDULE 13G/AApr 22, 2026No data0001104659-26-046924Document
6-KApr 20, 2026Apr 20, 20260001833141-26-000026Document
6-KApr 20, 2026Apr 20, 20260001833141-26-000024Document

Latest News

6 articles
RTTNewsJun 24, 2026, 12:00 AMnasdaq

Helus Pharma Surpasses 86% Enrollment In Phase 3 APPROACH Trial, Launches US $50 Million Offering

(RTTNews) - Helus Pharma (HELP) reported strong clinical and financial momentum as the company announced that its Phase 3 APPROACH trial has surpassed 86% enrolment, while also pricing a US$50 million underwritten offering to support advancement of its mental-health pipeline.

Open article
RTTNewsJun 24, 2026, 12:00 AMnasdaq

Helus Pharma Prices $50 Mln Share Offering; Stock Up In Pre-market

(RTTNews) - Drug developer, Cybin D/B/A Helus Pharma (HELP), announced on Wednesday that it has priced an underwritten offering of about 10.3 million common shares at $4.85 each to raise gross proceeds of $50 million.

Open article
FintelApr 13, 2026, 12:00 AMnasdaq

TD Cowen Initiates Coverage of Cybin (HELP) with Buy Recommendation

Fintel reports that on April 13, 2026, TD Cowen initiated coverage of Cybin (NasdaqGM:HELP) with a Buy recommendation. What are Other Shareholders Doing?

Open article
MarketBeatFeb 20, 2026, 12:00 AMnasdaq

Magic Mushrooms, Hard Cash: Compass Pathways’ Trial Win, Fast Raise

Treatment-Resistant Depression (TRD) stands as one of the most stubborn and costly challenges in modern healthcare. For the millions of patients who have cycled through multiple antidepressants without relief, the treatment landscape has long been a graveyard of failed promises

Open article
RTTNewsFeb 13, 2026, 12:00 AMnasdaq

Helus Pharma To Report Phase 2 Data For HLP004 In Generalized Anxiety Disorder This Quarter

(RTTNews) - HELUS Pharma (HELP) reported its third-quarter fiscal 2026 financial results, noting continued operational execution and advancement across its clinical-stage neuroscience programs. The company ended the quarter with a solid cash position and reiterated expectations f

Open article
RTTNewsFeb 10, 2026, 12:00 AMnasdaq

Helus Pharma Names Michael Cola CEO

(RTTNews) - Helus Pharma (HELP), a clinical stage pharmaceutical company, Tuesday announced the appointment of Michael Cola as Chief Executive Officer, effective immediately.

Open article